Long-term survival and complications following bladder-preserving brachytherapy in patients with cT1-T2 bladder cancer
Radical cystectomy (RC) is still considered standard of treatment for patients with non-metastatic muscle-invasive bladder cancer (MIBC) and high-risk non-muscle-invasive bladder cancer (NMIBC) refractory to intravesical therapy in most countries . However, RC has significant morbidity and mortality .
Conclusions: Higher dose volumes for the bladder and rectum predicted for poorer PR-QOL. In contrast to prostate brachytherapy data, neither prostate volume nor urethral dosimetry at this dose schedule correlated with urinary symptoms.
CONCLUSION: In selected patients with solitary, ≤5 cm cT1G3-T2N0M0 bladder tumours brachytherapy is a bladder-sparing therapy with good survival outcome and with a favourable complication rate compared to RC. PMID: 31630869 [PubMed - as supplied by publisher]
CONCLUSIONS: Higher dose volumes for the bladder and rectum predicted for poorer PR-QOL. In contrast to prostate brachytherapy data, neither prostate volume nor urethral dosimetry at this dose schedule correlated with urinary symptoms. PMID: 31584457 [PubMed - as supplied by publisher]
Abstract This review provides an overview of the current status of image registration for image guided gynaecological brachytherapy including combination with external beam radiotherapy. Contour propagation between individual fractions and dose accumulation can be useful for cervix cancer radiotherapy. Contour mapping and applicator reconstruction with rigid registration based on the applicator geometry provide good accuracy. However, deformable image registration is particularly challenging in the pelvic region, due to the large and complex deformations caused by tumor shrinkage, bladder and rectum filling, inser...
Conclusions: In 3D brachytherapy of cervical cancer, GO and IPSA optimizations do not present a significant difference in target dose coverage; nevertheless, IPSA may reduce the maximum dose to normal tissue when compared with GO. PMID: 31523240 [PubMed]
Conclusions: When the facilities for MR-compatible applicators are not available, MR-based ISBT is feasible with PEEK catheters using available resources for advanced cervical cancer. Doses to HR-CTV and IR-CTV were achieved, restricting doses to OARs as per GEC-ESTRO guidelines. PMID: 31523230 [PubMed]
CONCLUSIONS: IGABT using Vienna II applicator allows for appropriate target coverage in tumors extending into DP/LPW at the time of BT. Clinical use is feasible and results in good local control, DFS and OS with moderate rate of acute and late ≥G3 toxicity. PMID: 31495516 [PubMed - as supplied by publisher]
This study, for the first time, aims to quantify the impact of modulation restriction on plan quality indices in inverse optimization for cervix high-dose-rate (HDR) brachytherapy using the BEBIG SagiPlan treatment planning system. Material and methods: Ten cervical cancer patient plans were optimized for treatment with a BEBIG SagiNova 60Co HDR afterloader using the min/max inverse planning method, with dwell time homogeneity error weight (DTHEW) parameter values of 0 to 10. Dwell time homogeneity and gradients as well as various plan quality indices were analyzed. Results: For DTHEW = 0, min/max-based optimizatio...
CONCLUSION: Overall, the accelerated HDR IVB wassafe and was well tolerated in endometrial cancer patients and the incidence rate of undue complications were equal,if not less, in elderly patients compared to the younger ones. PMID: 31350963 [PubMed - in process]
Permanent seed prostate brachytherapy as monotherapy is a highly effective treatment option for men with low- and intermediate-risk prostate cancer, with long-term cancer control rates of 90% or higher. It has the convenience of a single treatment but often results in moderate urinary tract symptoms over a few months while the radiation is being delivered. Furthermore, seed loss or displacement can lead to suboptimal dosimetry, including cold areas within the prostate and higher dose than intended to urethra, rectum, and bladder.